Biomedical Research Education & Training
Faculty Member

Hande, Kenneth R., M.D.
Professor of Medicine
Professor of Pharmacology

Lab Url: N/A

Phone Number: 615-322-4967

Email Address: kenneth.r.hande@vanderbilt.edu

Hande, Kenneth's picture
Academic history
A.B., Princeton
M.D., Johns Hopkins

Office Address   Mailing Address

777 PRB 37232-6307


Publications
Hande, Kenneth R, Collier, Mary, Paradiso, Linda, Stuart-Smith, Jill, Dixon, Mary, Clendeninn, Neil, Yeun, Geoff, Alberti, Donna, Binger, Kim, Wilding, George. Phase I and pharmacokinetic study of prinomastat, a matrix metalloprotease inhibitor. Clin Cancer Res, 10(3), 909-15, 2004

Lockhart, A Craig, Howard, Martin, Hande, Kenneth R, Roth, Bruce J, Berlin, Jordan D, Vreeland, Franzanne, Campbell, Angela, Fontana, Erminia, Fiorentini, Francesca, Fowst, Camilla, Paty, Victoria A, Lankford, Odessa, Rothenberg, Mace L. A phase I dose-escalation and pharmacokinetic study of brostallicin (PNU-166196A), a novel DNA minor groove binder, in adult patients with advanced solid tumors. Clin Cancer Res, 10(2), 468-75, 2004

Clapp JM and Hande KR. Topoisomerase II inhibitors. In Cancer Chemotherapy and Biological Response Modifiers, Annual 19. 125-149, 2002.

Hande KR. Purine Antimetabolites. In Encyclopedia of Cancer, 2nd Edition. JR Bertino ed. Academic Press, Amsterdam, 515-525, 2002.

Clapp, JaNae M, Hande, Kenneth R. Topoisomerase II inhibitors. Cancer Chemother Biol Response Modif, 20, 125-49, 2002

44. Hande KR. Purine Antimetabolites. In Cancer Chemotherapy and Biotherapy: Principles and Practice, 3rd edition. BA Chabner and DL Longo, eds. Lippincott Williams & Wilkins, Philadelphia, 295-314, 2001.

Dowell JE, Garrett AM, Shyr Y, Johnson, DA, Hande KR. A randomized Phase II trial in patients with carcinoma of unknown primary, Cancer 91:592-596, 2001.

Toonen TR, Hande KR. Topoisomerase II inhibitors. In Cancer Chemotherapy and Biological Response Modifiers, Annual 19. 129-147, 2001.

Choy, H, DeVore, R F, Hande, K R, Porter, L L, Rosenblatt, P A, Slovis, B, Laporte, K, Shyr, Y, Johnson, D H, , . Phase I trial of outpatient weekly docetaxel, carboplatin and concurrent thoracic radiation therapy for stage III unresectable non-small-cell lung cancer: a Vanderbilt cancer center affiliate network (VCCAN) trial. Lung Cancer, 34(3), 441-9, 2001

Dowell, J E, Garrett, A M, Shyr, Y, Johnson, D H, Hande, K R. A randomized Phase II trial in patients with carcinoma of an unknown primary site. Cancer, 91(3), 592-7, 2001

Toonen, T R, Hande, K R. Topoisomerase II inhibitors. Cancer Chemother Biol Response Modif, 19, 129-47, 2001

Choy H, DeVore RF, Hande KR et al. A Phase I outpatient trial of weekly Docetaxel and concurrent radiation therapy for stage III unresectable non-small cell lung cancer: A Vanderbilt Cancer Center Affiliate Network trial. Clinical Lung Cancer 1:27-31, 2000.

Choy H, DeVore RF, Hande KR, et al. A Phase II study of paclitaxel, carboplatin and hyperfractionated radiation therapy for locally inoperable non-small cell lung cancer. Int J Rad Onc Biol Phys 47:931-937, 2000.

Dang TP, Gazdar AF, Virmani AK, Sepetavec T, Hande KR, Minna JD, Roberts JR, Carbone DP. Chromosome 19 translocation, overexpression, of Notch 3 and human lung cancer. J Natl Cancer Inst. 92:1355-1357, 2000.

Hande KR. Chemotherapy In Lung Cancer: Principles and Practice. H Pass, J Mitchell, D Johnson, A Turrisi and J Minna eds. Lippincott Williams & Wilkins, Philadelphia, Pa, pp 270-283, 2000.

Nicholson BP, Paul DM, Hande KR, Shyr Y, Meshad M,Cohen A, Johnson DH. Paclitaxel, 5-fluorouracil, and leucovorin (TFL) in the treatment of metastatic breast cancer. Clin Breast Cancer 1:136-143, 2000.

Choy, H, Chakravarthy, A, Devore, R F, Jagasia, M, Hande, K R, Roberts, J R, Johnson, D H, Yunus, F. Weekly irinotecan and concurrent radiation therapy for stage III unresectable NSCLC. Oncology (Huntingt), 14(7 Suppl 5), 43-6, 2000

Choy, H, De Vore, R F, Hande, K R, Porter, L L, Rosenblatt, P A, Slovis, B, Laporte, K, Shyr, Y, Johnson, D H. A Phase I Trial of Outpatient Weekly Docetaxel and Concurrent Radiation Therapy for Stage III Unresectable Non Small-Cell Lung Cancer: A Vanderbilt Cancer Center Affiliate Network (VCCAN) Trial. Clin Lung Cancer, 1 Suppl 1, S27-31, 2000

Choy, H, Devore, R F, Hande, K R, Porter, L L, Rosenblatt, P, Yunus, F, Schlabach, L, Smith, C, Shyr, Y, Johnson, D H. A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study). Int J Radiat Oncol Biol Phys, 47(4), 931-7, 2000

Dang, T P, Gazdar, A F, Virmani, A K, Sepetavec, T, Hande, K R, Minna, J D, Roberts, J R, Carbone, D P. Chromosome 19 translocation, overexpression of Notch3, and human lung cancer. J Natl Cancer Inst, 92(16), 1355-7, 2000

Nicholson, B P, Paul, D M, Hande, K R, Shyr, Y, Meshad, M, Cohen, A, Johnson, D H. Paclitaxel, 5-fluorouracil, and leucovorin (TFL) in the treatment of metastatic breast cancer. Clin Breast Cancer, 1(2), 136-43; discussion 144, 2000

Grunberg SM, Crowley J, Hande KR, et al. Treatment of poor prognosis, extensive disease small-cell lung cancer with an all-oral regimen of etoposide and cyclophosphamide?a Southwest Oncology Group clinical and pharmacokinetic study. Cancer Chemother Pharmacol 44:461-468, 1999.

Hande K, Messenger M, Wagner J, Krozely M, and Kaul S. Inter- and intrapatient variability in etoposide kinetics with oral and intravenous drug administration. Cancer Clin Res 5:2742-2747, 1999.

Hande KR. Principles and Pharmacology of Chemotherapy in Wintrobe?s Clinical Hematology. Lee GR, Foester J, Lukens J, Paraskeves F, Greer JP, and Rogers GM eds. Williams & Wilkins, Baltimore, pp 2076-2101, 1999.

Rothenberg ML, Nelson AR, and Hande KR. Matrix metalloproteinase inhibitors. Stem Cells 17:237-240, 1999.

Rothenberg, M L, Nelson, A R, Hande, K R. New drugs on the horizon: matrix metalloproteinase inhibitors. Stem Cells, 17(4), 237-40, 1999

Goren MP, Anthony LB, Hande KR, et al. Pharmacokinetics of an intravenous?oral vs. intravenous MESNA regimen in lung cancer patients receiving ifosfamide. J Clin Oncol 16:616-621, 1998.

Hande KR. Clinical applications of anticancer drugs targeted to topoisomerase II. Biochemica et Biophysica Acta 1400:173-184, 1998.

Hande KR.Etoposide:Four decades of development of a topoisomerase II inhibitor. Eur J Cancer 34:1514-1521,1998.

Rothenberg ML, Nelson AR, and Hande KR. New drugs on the horizon: matrix metalloproteinase inhibitors. The Oncologist 3:271-274, 1998.

Hande, K R. Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer, 34(10), 1514-21, 1998

Hande, K R. Clinical applications of anticancer drugs targeted to topoisomerase II. Biochim Biophys Acta, 1400(1-3), 173-84, 1998

Rothenberg, , Nelson, , Hande, . New Drugs on the Horizon: Matrix Metalloproteinase Inhibitors. Oncologist, 3(4), 271-274, 1998

Choy, H, DeVore, R F, Hande, K R, Porter, L L, Rosenblatt, P, Yunus, F, Schlabach, L, Smith, C, Shyr, Y, LaPorte, K, Johnson, D H. Preliminary analysis of a phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small cell lung cancer. Semin Oncol, 24(4 Suppl 12), S12-21-S12-26, 1997

Johnson, D H, Paul, D, Hande, K R. Paclitaxel, 5-fluorouracil, and folinic acid in metastatic breast cancer: BRE-26, a phase II trial. Semin Oncol, 24(1 Suppl 3), S22-5, 1997

Nicholson, B, Paul, D, Shyr, Y, Garrett, M, Hande, K R, Johnson, D H. Paclitaxel/5-fluorouracil/leucovorin in metastatic breast cancer: a Vanderbilt Cancer Center phase II trial. Semin Oncol, 24(4 Suppl 11), S11-20-S11-23, 1997

Deegan PM, Basinger MA, Jones MM, and Hande KR. Prevention of cisplatin nephrotoxicity exogenous atrial naturetic peptide. Toxicology 106:159-166, 1996.

Hande KR. The importance of drug scheduling in cancer chemotherapy: etoposide as an example. Stem Cells14:18-24, 1996.

Johnson DH, Paul DP, Hande KR, Shyr Y, Blanke C, Murphy B, Lewis M, and DeVore RF. Paclitaxel plus carboplatin in advanced non-small cell lung cancer. A Phase II trial. J Clin Oncol 14:2054-2060, 1996.

Deegan, P M, Basinger, M A, Jones, M M, Hande, K R. Prevention of cisplatin nephrotoxicity by exogenous atrial natriuretic peptide. Toxicology, 106(1-3), 159-66, 1996

Hande, . The Importance of Drug Scheduling in Cancer Chemotherapy: Etoposide as an Example. Oncologist, 1(4), 234-239, 1996

Hande, K R. The importance of drug scheduling in cancer chemotherapy: etoposide as an example. Stem Cells, 14(1), 18-24, 1996

Johnson, D H, Paul, D M, Hande, K R, DeVore, R. Paclitaxel plus carboplatin in the treatment of patients with advanced lung cancer: a Vanderbilt University Cancer Center phase II trial (LUN-46). Semin Oncol, 23(6 Suppl 16), 42-6, 1996

Johnson, D H, Paul, D M, Hande, K R, Shyr, Y, Blanke, C, Murphy, B, Lewis, M, De Vore, R F. Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial. J Clin Oncol, 14(7), 2054-60, 1996

Anthony LA, Boeve TJ, and Hande KR. Cytochrome P-450IID6 phenotyping in cancer patients: debrisoquin and dextromethorphan as probes. Cancer Chemother Pharmacol 36:125-128, 1995.

Deegan PM, Nolan C, Ryan MP, Basinger MA, Jones MM, and Hande KR. The role of the renin-angiotensin system in cisplatin toxicity. Renal Failure 17:665-674, 1995.

Deegan PM, Ryan MP, Bassinger MA, Jones MM, and Hande KR. Protection from cisplatin nephrotoxicity by A68828, an atrial naturetic peptide. Renal Failure 17:117-123, 1995.

Thompson DS, Greco FA, Miller AA, Srinivas NR, Igwemezie LN, Hainsworth JD, Schacter LP, Kaul S, Babhaiya RH, Garrow GC, and Hande KR. A Phase I study of etoposide phosphate administered as a daily 30-minute infusion for 5 days. Clin Pharmacol Ther 57:499-507, 1995.

Anthony, L B, Boeve, T J, Hande, K R. Cytochrome P-450IID6 phenotyping in cancer patients: debrisoquin and dextromethorphan as probes. Cancer Chemother Pharmacol, 36(2), 125-8, 1995

Deegan, P M, Nolan, C, Ryan, M P, Basinger, M A, Jones, M M, Hande, K R. The role of the renin-angiotensin system in cisplatin nephrotoxicity. Ren Fail, 17(6), 665-74, 1995

Deegan, P M, Ryan, M P, Basinger, M A, Jones, M M, Hande, K R. Protection from cisplatin nephrotoxicity by A68828, an atrial natriuretic peptide. Ren Fail, 17(2), 117-23, 1995

Johnson, D H, Paul, D M, Hande, K R, DeVore, R F. Paclitaxel plus carboplatin for advanced lung cancer: preliminary results of a Vanderbilt University phase II trial--LUN-46. Semin Oncol, 22(4 Suppl 9), 30-3, 1995

Thompson, D S, Hainsworth, J D, Hande, K R, Holzmer, M, Greco, F A. Prolonged administration of low dose infusional etoposide in patients with advanced malignancies. A phase I/II study. Cancer, 73(11), 2824-31, 1994

Anthony L, Johnson D, Hande K, Winn S, Krozley M, and Oates J. Somatostatin analogue Phase I trials in neuroendocrine tumors. Acta Oncologica 32:217-223, 1993.

Hande KR and Garrow GC. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin?s lymphoma. Am J.Med 94:133-130, 1993.

Hande KR and Garrow GC. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin?s lymphoma. Am J.Med 94:133-130, 1993.

Hande KR, Krozley MG, Greco FA, et al. Bioavailability of low dose oral etoposide. J Clin Oncol 11:374-377, 1993.

Hande KR. Pharmacologic-based dosing of carboplatinum: A better method. J Clin Oncol 11:2295-2296, 1993.

Thompson DS, Hainsworth JD, Hande KR, et al. Prolonged administration of low-dose infusional etoposide in patients with etoposide-sensitive neoplasms: A phase I/II study. J Clin Oncol 11:1322-1328, 1993.

Hande, K R, Garrow, G C. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. Am J Med, 94(2), 133-9, 1993

Hande, K R, Krozely, M G, Greco, F A, Hainsworth, J D, Johnson, D H. Bioavailability of low-dose oral etoposide. J Clin Oncol, 11(2), 374-7, 1993

Thompson, D S, Hainsworth, J D, Hande, K R, Holzmer, M C, Greco, F A. Prolonged administration of low-dose, infusional etoposide in patients with etoposide-sensitive neoplasms: a phase I/II study. J Clin Oncol, 11(7), 1322-8, 1993

Hande KR. Antitumor antibiotics, epipodophyllotoxins and vinca alkaloids. Curr Opin Oncol 4:1080 1088, 1992.

Hande KR. Etoposide Pharmacology. Sem Oncol 19:(suppl) 3 9, 1992.

Ormond PM, Basinger MA, Jones MM, and Hande KR. Association between increased atrial naturetic peptide and reduced cisplatin nephrotoxicity in rats. J Pharm Exp Ther 262:246 251, 1992.

Waites TM, Johnson DH, Hainsworth JD, Hande KR, Thomas M, and Greco FA. Prolonged administration of oral etoposide in non small cell lung cancer: A Phase II trial. J Clin Oncol 10:292 296, 1992.

Greco, F A, Murphy, P B, Hainsworth, J D, Hande, K R, Johnson, D H. Prolonged administration of oral etoposide plus cisplatin in extensive stage small cell lung cancer. Oncology, 49 Suppl 1, 34-8; discussion 39, 1992

Hande, K R. Antitumor antibiotics, epipodophyllotoxins, and vinca alkaloids. Curr Opin Oncol, 4(6), 1080-8, 1992

Hande, K R. Etoposide pharmacology. Semin Oncol, 19(6 Suppl 13), 3-9, 1992

Johnson, D H, DeVore, R, Greco, F A, Walls, J, Thomas, M, Hande, K R, Hainsworth, J D. Carboplatin plus oral etoposide in the management of advanced, non-small cell lung cancer: preliminary results of a Vanderbilt trial. Semin Oncol, 19(1 Suppl 2), 50-6, 1992

Johnson, D H, Hainsworth, J D, DeVore, R, Hande, K R, Greco, F A. Carboplatin plus oral etoposide in the management of unresectable non-small cell lung cancer. Preliminary results of a Vanderbilt trial. Oncology, 49 Suppl 1, 57-61; discussion 61-2, 1992

Johnson, D H, Hainsworth, J D, Hande, K R, Greco, F A. Combination chemotherapy with oral etoposide. Semin Oncol, 19(6 Suppl 14), 19-24, 1992

Murphy, P B, Hainsworth, J D, Greco, F A, Hande, K R, DeVore, R F, Johnson, D H. A phase II trial of cisplatin and prolonged administration of oral etoposide in extensive-stage small cell lung cancer. Cancer, 69(2), 370-5, 1992

Ormond, P M, Basinger, M A, Jones, M M, Hande, K R. Association between increased atrial natriuretic peptide and reduced cisplatin nephrotoxicity in rats. J Pharmacol Exp Ther, 262(1), 246-51, 1992

Waits, T M, Johnson, D H, Hainsworth, J D, Hande, K R, Thomas, M, Greco, F A. Prolonged administration of oral etoposide in non-small-cell lung cancer: a phase II trial. J Clin Oncol, 10(2), 292-6, 1992

Hande KR. Drug monitoring in cancer therapy. J Natl Cancer Inst 83:1523 1524, 1991.

Johnson, D H, Hainsworth, J D, Hande, K R, Greco, F A. Current status of etoposide in the management of small cell lung cancer. Cancer, 67(1 Suppl), 231-44, 1991

Johnson, D H, Strupp, J, Greco, F A, Stewart, J, Merrill, W, Malcolm, A, Hande, K R, Hainsworth, J D. Neoadjuvant cisplatin plus vinblastine chemotherapy in locally advanced non-small cell lung cancer. Cancer, 68(6), 1216-20, 1991

Anthony LB, Long QC, Struck SF and Hande KR. The effect of cimetidine on cyclophosphamide metabolism in rabbits. Cancer Chemother Pharmacol 27:125 130, 1990.

Hande, KR, Kuttesch, J, Hamilton, M, Satterlee, et al. Kinetics of N [(4 Chlorophenyl) amino] carbonyl 2,3, dihydro lH indene sulfonamide in man. Cancer Research 51:3910 3914, 1990.

Hande, KR, Wolff, SN, Greco, FA, Hainsworth, JD, Reed, G, and Johnson, DH. Etoposide kinetics in patients with obstructive jaundice. J Clin Oncol 8:1101 1107, 1990.

Johnson, DH, Greco, FA, Strupp, J, Hande KR, and Hainsworth, JD. Prolonged administration of oral etoposide in patients with relapsed or refractory small cell lung cancer: A Phase II trial. J Clin Oncol 8:1613 1617, 1990.

Anthony, L B, Long, Q C, Struck, R F, Hande, K R. The effect of cimetidine on cyclophosphamide metabolism in rabbits. Cancer Chemother Pharmacol, 27(2), 125-30, 1990

Hande, K R, Kuttesch, J, Hamilton, M, Satterlee, W, Jackson, L, Grindey, G, Hainsworth, J D. Kinetics of N-[(4-chlorophenyl)amino]carbonyl-2,3-dihydro-1H-indene-5-sulfonamide (LY186641) in humans. Cancer Res, 50(13), 3910-4, 1990

Hande, K R, Wolff, S N, Greco, F A, Hainsworth, J D, Reed, G, Johnson, D H. Etoposide kinetics in patients with obstructive jaundice. J Clin Oncol, 8(6), 1101-7, 1990

Johnson, D H, Greco, F A, Strupp, J, Hande, K R, Hainsworth, J D. Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial. J Clin Oncol, 8(10), 1613-7, 1990

Hainsworth, JD, Hande, KR, Satterlee, WG, Kuttesch, et al. Phase I clinical study of N-[(4-Chlorophenyl) amino] carbony1 2,3-dihydro-1H indene-5-sulfonamide (LY186641). Cancer Res 49:5217-5220, 1989.

Mangum, M, Greco, FA, Hainsworth, Hande, KR and Johnson, DH. Combined small-cell and non-small cell lung cancer. J. Clin Oncol, 7:607-612, 1989

Hainsworth, J D, Hande, K R, Satterlee, W G, Kuttesch, J, Johnson, D H, Grindey, G, Jackson, L E, Greco, F A. Phase I clinical study of N-[(4-chlorophenyl)amino]carbonyl-2,3-dihydro-1H-indene-5-sulfonamide (LY186641). Cancer Res, 49(18), 5217-20, 1989

Hainsworth, J D, Johnson, D H, Hande, K R, Greco, F A. Chemotherapy of advanced non-small-cell lung cancer: a randomized trial of three cis-platin-based chemotherapy regimens. Am J Clin Oncol, 12(4), 345-9, 1989

Mangum, M D, Greco, F A, Hainsworth, J D, Hande, K R, Johnson, D H. Combined small-cell and non-small-cell lung cancer. J Clin Oncol, 7(5), 607-12, 1989

Dessypris, E.N., Brenner, D.E., Baer, M.R., and Hande, K.R. Uptake and intracellular distribution of doxorubicin metabolites in B-lymphocytes of chronic lymphocytic leukemia. Cancer Res, 48:503-506, 1988.

Hande, K.R., Anthony, L.B., Hamilton, R., Bennett, R., Sweetman, B. and Branch, R. Identification of etoposide glucuronide as a major metabolite of etoposide in the rat and rabbit. Cancer Res 48:1829-1834, 1988.

Hande, KR, Bennett, R, Hamilton, R, Grote, T, and Branch, R. Metabolism and excretion of etoposide in isolated perfused rat liver models. Cancer Res, 48:5692-5695, 1988.

List, AF, Greer, JP, Cousar, JC, Stein RS, Johnson DH, Reynolds VH, Greco, FA, Flexner, JM and Hande, KR. Non-Hodgkin's lymphoma of the gastrointestinal tract: An analysis of clinical and pathological features affecting outcome. J. Clin Oncol, 6:1125-1133, 1988.

List, A F, Greer, J P, Cousar, J C, Stein, R S, Johnson, D H, Reynolds, V H, Greco, F A, Flexner, J M, Hande, K R. Non-Hodgkin's lymphoma of the gastrointestinal tract: an analysis of clinical and pathologic features affecting outcome. J Clin Oncol, 6(7), 1125-33, 1988

Brenner, D.E., Anthony, L.B., Halter, S., Harris, N.L., and Hande, K.R. Effects of ethyl alcohol-induced sublethal hepatic damage upon doxorubicin metabolism and toxicity in the rabbit. Cancer Res 47:3259-3265, 1987.

Wolff, S.N., Grosh, W.W., Prater, K., and Hande, K.R. In vitro pharmacodynamic evaluation of VP-16-213 and implications for chemotherapy. Cancer Chemother Pharmacol 19:246-249, 1987.

Johnson, D H, Porter, L L, List, A F, Hande, K R, Hainsworth, J D, Greco, F A. Acute nonlymphocytic leukemia after treatment of small cell lung cancer. Am J Med, 81(6), 962-8, 1986


Postdoctoral Position Available
N/A

Postdoctoral Position Details
N/A

Updated Date
06/03/2003